Actively Recruiting
Long-term Follow-up Study to Evaluate Participants With Chronic Hepatitis B (CHB) Previously Treated With AHB-137 Injection
Led by Ausper Biopharma Co., Ltd. · Updated on 2026-05-04
200
Participants Needed
2
Research Sites
226 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study is a prospective, open-label, multicenter long-term follow-up study to evaluate the durability of virologic response in subjects with chronic hepatitis B previously treated with AHB-137 injection.
CONDITIONS
Official Title
Long-term Follow-up Study to Evaluate Participants With Chronic Hepatitis B (CHB) Previously Treated With AHB-137 Injection
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Able to give informed consent
- Previously received at least one dose of AHB-137 injection
- Achieved complete or partial response in prior study without rescue medication
- Maintained response until the end of their previous study visit
You will not qualify if you...
- Currently participating in another interventional clinical study after AHB-137 treatment
- Suspected cancer at screening
- Any condition requiring hospitalization during this study
- Any condition that the investigator or Medical Monitor believes prevents participation
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
AusperBio Investigational Site
Guangzhou, Guangdong, China
Actively Recruiting
2
AusperBio Investigational Site
Changchun, Jilin, China
Actively Recruiting
Research Team
L
Lu
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here